Target intelligence / Profile preview

HLA class I histocompatibility antigen, A alpha chain (HLA-A*02:01) (HLA-A*02:01)

Target
HLA-A*02:01
Molecular classification
Receptor, Other
01

Overview

HLA-A*02:01 is a highly prevalent allele of the HLA class I histocompatibility antigen, A alpha chain (HLA-A), which plays a critical role in the adaptive immune system. It forms a heterotrimeric complex with beta-2 microglobulin and intracellularly derived peptide antigens, presenting them on the cell surface for recognition by CD8-positive cytotoxic T cells. In oncology, HLA-A*02:01 is a pivotal therapeutic target because it presents tumor-associated antigens (such as gp100 and MAGE-A4) that can be targeted by engineered T-cell receptors (TCRs) and bispecific T-cell engagers. Drugs like tebentafusp (Kimmtrak) and afamitresgene autoleucel (Tecelra) are specifically designed to bind to these peptide-HLA-A*02:01 complexes, bridging cancer cells with T cells to induce tumor lysis. However, because HLA-A*02:01 expression varies significantly across ethnic populations, therapies restricted to this allele face challenges regarding equitable patient access. Additionally, therapeutic targeting of this complex is associated with safety concerns such as cytokine release syndrome and on-target, off-tumor toxicities in normal tissues expressing the target antigen.

Other names
HLA-A*0201HLA-A*02:01Human leukocyte antigen A*02:01MHC class I antigen HLA-A*0201Major histocompatibility complex class I, A*02:01HLA-A2
02

Mechanism of action

Bispecific T-cell engager (ImmTAC) that redirects CD3+ T cells to target gp100 peptide presented by HLA-A*02:01; T-cell receptor (TCR) engineered T-cell therapy targeting MAGE-A4 peptide presented by HLA-A*02:01

03

Biological functions

Immune responseOther
04

Disease associations

CancerInfectionInflammation
05

Safety considerations

Cytokine release syndrome (CRS)On-target, off-tumor toxicity (e.g., skin reactions/rash due to gp100 expression in normal melanocytes)Immune-related adverse events (irAEs)Severe cytopenias (associated with lymphodepleting chemotherapy prior to TCR-T therapy)
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

HLA-A*02:01 genotypegp100 expressionMAGE-A4 expression

Beyond the preview

Go deeper on HLA class I histocompatibility antigen, A alpha chain (HLA-A*02:01) (HLA-A*02:01).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA class I histocompatibility antigen, A alpha chain (HLA-A*02:01) (HLA-A*02:01).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call